Prevention of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis
- 10 September 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Pharmacy
- Vol. 43 (1), 25-34
- https://doi.org/10.1007/s11096-020-01146-6
Abstract
Background Anthracycline based chemotherapy is commonly used in many malignancies. While life expectancy increases with the use of this medication, cardiac toxicity causes a risk for patients’ health due to anthracyclines. Objective This systematic review and meta-analysis emphasizes on prevention of anthracycline-associated cardiotoxicity in breast cancer and lymphoma patients. Methods We conducted a systematic review of electronic databases including PubMed, Medline, EMBASE, ClinicalTrials.gov, Web of Science, and the Cochrane Library from inception to June 2019 collecting published articles on primary prevention of anthracycline-associated cardiotoxicity in breast cancer and lymphoma patients. We conducted a network meta-analysis and a pairwise meta-analysis in order to compare direct and indirect cardiac agents group with control group calculate left ventricular ejection fraction change. Primary studies results were pooled using random effects model, frequent network meta-analyses, and performed pairwise meta-analysis using netmeta and meta packages respectively in R software version 3.5.1. Results Twelve studies reported left ventricular ejection fraction outcome among 526 patients in the cardiac agent group and 508 in the control group. Based on Surface Under the Cumulative Ranking cure result, spironolactone was the best in left ventricular ejection fraction change and based on meta-analysis, cardiac group had 1.98 unit left ventricular ejection fraction more than the control group (MD = 1.98, 95% CI 0.15–3.81, p value = 0.03). Conclusions The amount of left ventricular ejection fraction used by cardiac agents in anthracycline-based chemotherapy was reduced to a lesser extent. The effective and ineffective drugs were spironolactone and metoprolol, respectively.Keywords
This publication has 38 references indexed in Scilit:
- Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control studyInternational Journal of Cardiology, 2013
- Evaluation of Short-Term Use of N-Acetylcysteine as a Strategy for Prevention of Anthracycline-Induced Cardiomyopathy: EPOCH Trial - A Prospective Randomized StudyKorean Circulation Journal, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Effects of Statin Treatment on Cardiac Function in Patients With Chronic Heart Failure: A Meta‐Analysis of Randomized Controlled TrialsClinical Cardiology, 2010
- Effect of Spironolactone on Left Ventricular Ejection Fraction and Volumes in Patients With Class I or II Heart FailureThe American Journal of Cardiology, 2010
- Cardioprotective effect of metoprolol and enalapril in doxorubicin‐treated lymphoma patients: A prospective, parallel‐group, randomized, controlled study with 36‐month follow‐upAmerican Journal of Hematology, 2010
- Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trialsBMC Cancer, 2010
- Recovery From Anthracycline Cardiomyopathy–How can it be Explained?The Journal of Heart and Lung Transplantation, 2009
- GRADE: assessing the quality of evidence for diagnostic recommendationsBMJ Evidence-Based Medicine, 2008
- Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapyAnnals Of Oncology, 2006